Answers are grounded in this paper and cite their sources.
Trastuzumab is a monoclonal antibody targeting HER-2. HER-2 overexpression has been described in gallbladder cancer and in cholangiocarcinoma. This report describes the first case of a patient with HER-2 overexpressing metastatic gallbladder adenocarcinoma and responding radiographically and biochemically to trastuzumab alone.
No takes yet. Share an insight, caveat, or question.
Steven Sorscher (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: